Intervention

Enavogliflozin

ClinicalTrials.gov intervention label

Clinical trials7

Recruiting5

Common conditions10

Lead sponsors shown6

Clinical trials

7 shown

Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter AblationNCT06528262 · 2025-04-03

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in ObesityNCT06782139 · 2025-01-20

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve ReplacementNCT05672836 · 2024-12-18

Enavogliflozin vs. Pioglitazone on Glucose and AtherosclerosisNCT06399835 · 2024-02-01

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus PatientsNCT06642623 · 2024-01-22

Enavogliflozin Outcome Trial in Functional Tricuspid RegurgitationNCT06027307 · 2023-10-25

ACTIVE_NOT_RECRUITING

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes MellitusNCT05926414 · 2023-09-21

ACTIVE_NOT_RECRUITING

Common conditions

Diabetes Mellitus, Type 22 Aortic Valve Stenosis1 Atrial Fibrillation1 Cardiovascular Diseases1 Heart Failure1 Heart Failure With Preserved Ejection Fraction1 Kidney Diseases1 Obesity and Type 2 Diabetes1 Tricuspid Regurgitation1 Type 2 Diabetes1

Leading sponsors

Yonsei University2 Asan Medical Center1 Daewoong Pharmaceutical Co. LTD.1 Duk-Woo Park, MD1 Korea University Anam Hospital1 Seoul National University Bundang Hospital1

Trial status mix

RECRUITING5

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE45

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.